1. Duration of delirium: league table of posterior median pairwise RoM and 95% CrI (lower triangle), and pairwise probabilities that a treatment is better than another (upper triangle).

Alpha2 agonist	0.807	0.819	0.907	0.922	0.977	0.938
0.72 (0.33, 1.87)	Atypical antipsychotic	0.610	0.858	0.861	0.975	0.927
0.66 (0.21, 2.13)	0.92 (0.36, 2.11)	Opioid	0.627	0.685	0.924	0.660
0.60 (0.26, 1.48)	0.84 (0.50, 1.25)	0.92 (0.42, 1.97)	Typical antipsychotic	0.646	0.945	0.607
0.55 (0.22, 1.43)	0.77 (0.37, 1.38)	0.84 (0.30, 2.25)	0.92 (0.47, 1.73)	Statin	0.909	0.396
0.31 (0.10, 0.97)	0.44 (0.17, 1.00)	0.48 (0.14, 1.51)	0.52 (0.21, 1.25)	0.57 (0.22, 1.49)	CHE Inhibitor	0.054
0.58 (0.26, 1.27)	0.80 (0.50, 1.11)	0.88 (0.37, 2.01)	0.96 (0.64, 1.36)	1.05 (0.61, 1.77)	1.84 (0.82, 4.10)	Placebo

CHE: cholinesterase.

Crl: credible interval.

RoM: ratio of means.

A complete summary of estimates for efficacy from the random‐effects (RE) consistency model assuming vague priors is displayed.

Treatments other than placebo are in the order of decreasing surface under the cumulative ranking curve (SUCRA) value from upper left to lower right. For each comparison, the lower/right‐most treatment is the reference treatment. For example, the RoM estimate of 0.58 (95% CrI 0.26 to 1.27) in the lower triangle suggests a 42% reduction in the mean duration of delirium with alpha₂ agonists compared to placebo. The corresponding probability estimate in the upper triangle suggests a probability of 93.8% that alpha₂ agonists are better than placebo in terms of duration of delirium. Estimates which ruled out the possibility of no difference based on pairwise RoM estimates are shown in bold font.